Pomalidomide/Selected CYP1A2 or CYP3A4 Inducers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines, including carbamazepine, nafcillin, phenobarbital, phenytoin, rifabutin, rifampin and St. John's wort may cause your body to breakdown and process your pomalidomide more quickly.
What might happen:
The amount of pomalidomide in your blood may decrease and it may not work as well at treating your cancer.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change or adjust the dose of your medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 2013 Feb;71(2):489-501.
2.Pomalyst (pomalidomide) US prescribing information. Celgene Corporation February, 2013.
3.Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx August 18, 2011.
4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
